文献速递前列腺增生与排尿功能障碍

维贝格龙治疗膀胱过度活动症的随机双盲安慰剂对照3期研究

Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.
PubMed 文献 · Eur Urol · 2018-02-01

本研究纳入1232例日本膀胱过度活动症(OAB)患者,随机接受维贝格龙50mg或100mg每日一次、安慰剂或咪达那新治疗12周。维贝格龙50mg和100mg在主要终点(每日排尿次数变化)和次要终点上均显著优于安慰剂,并显著改善生活质量,药物相关不良事件发生率与安慰剂相似且低于咪达那新。结论认为维贝格龙12周治疗有效且耐受良好。

要点

  • 维贝格龙50mg和100mg每日一次治疗12周,在减少每日排尿次数上显著优于安慰剂。
  • 维贝格龙显著改善尿急、急迫性尿失禁、尿失禁和夜尿症等症状变量及生活质量。
  • 药物相关不良事件发生率:维贝格龙50mg为7.6%,100mg为5.4%,安慰剂为5.1%,咪达那新为10.3%。

核心结论

  • 维贝格龙50mg或100mg每日一次治疗12周对OAB患者有效且耐受良好。

研究设计与样本

  • 随机、双盲、安慰剂对照3期研究,纳入1232例日本OAB患者,随机分配至维贝格龙50mg每日一次、100mg每日一次、安慰剂或咪达那新0.1mg每日两次,治疗12周。

主要发现

  • 维贝格龙50mg和100mg组在主要终点(第12周每日平均排尿次数较基线变化)和次要终点上均显著优于安慰剂。
  • 维贝格龙组排尿正常化、尿急缓解、急迫性尿失禁缓解和尿失禁缓解的患者比例显著高于安慰剂组。
  • 维贝格龙显著改善生活质量,患者满意度高。
  • 药物相关不良事件发生率:维贝格龙50mg组7.6%,100mg组5.4%,安慰剂组5.1%,咪达那新组10.3%。

临床怎么用

  • 对于OAB患者,可考虑使用维贝格龙50mg或100mg每日一次治疗12周,以改善排尿次数、尿急、尿失禁等症状及生活质量。

局限性

  • 治疗仅持续12周,需要长期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vibegron is a novel, potent, and selective β3-adrenoreceptor agonist for the treatment of patients with overactive bladder (OAB). OBJECTIVE: To evaluate the efficacy and safety of vibegron versus placebo in Japanese OAB patients. DESIGN, SETTING, AND PARTICIPANTS: Patients with OAB entered a 2-wk placebo run-in phase. Once eligibility (≥8 micturition/d and either ≥1 urgency episodes/d or ≥1 urgency incontinence episodes/d) was confirmed, patients entered a 12-wk double-blind treatment phase. The anticholinergic imidafenacin was used as an active reference. INTERVENTION: A total of 1232 patients were randomly assigned to one of the four 12-wk treatment groups: vibegron (50mg or 100mg once daily), placebo, or imidafenacin (0.1mg twice daily). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was change in the mean number of micturitions/d at wk 12 from baseline. The secondary endpoints were changes from baselines in OAB symptom variables (daily episodes of urgency, urgency incontinence, incontinence, and nocturia, and voided volume/micturition). Quality of life (QoL) and safety were assessed. A constrained longitudinal data analysis model was used for analysis of efficacy. RESULTS AND LIMITATIONS: Patients taking vibegron 50mg and 100mg orally for 12 wk had significant improvements over the placebo in the primary and secondary endpoints. The proportions of patients with normalization of micturition, resolution of urgency, urgency incontinence, and incontinence were significantly greater than placebo. Vibegron significantly improved QoL, with high patient satisfaction. Incidences of drug-related adverse events with vibegron 50mg and 100mg were 7.6%, 5.4%, similar to placebo (5.1%), and less than imidafenacin (10.3%). Treatment was for just 12 wk and a long-term study is needed. CONCLUSIONS: The 12-wk treatment with vibegron is effective and well tolerated in patients with OAB. PATIENT SUMMARY: This randomized study demonstrated that vibegron is clinically useful for treatment of patients with OAB. Trial registration JapicCTI-152936. http://www.clinicaltrials.jp/user/cteDetail.jsp.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. Eur Urol. 2018. PMID: 29366513. doi:10.1016/j.eururo.2017.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。